Jerusalem Pharmaceuticals Co. Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 10.83 million compared to USD 11.86 million a year ago. Net income was USD 1.64 million compared to USD 1.72 million a year ago. Basic earnings per share from continuing operations was USD 0.091 compared to USD 0.096 a year ago.
For the nine months, sales was USD 31.72 million compared to USD 31.7 million a year ago. Net income was USD 4.08 million compared to USD 2.95 million a year ago. Basic earnings per share from continuing operations was USD 0.227 compared to USD 0.164 a year ago.